1. Home
  2. CYTK vs JHG Comparison

CYTK vs JHG Comparison

Compare CYTK & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • JHG
  • Stock Information
  • Founded
  • CYTK 1997
  • JHG 1934
  • Country
  • CYTK United States
  • JHG United Kingdom
  • Employees
  • CYTK 564
  • JHG N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • JHG Investment Managers
  • Sector
  • CYTK Health Care
  • JHG Finance
  • Exchange
  • CYTK Nasdaq
  • JHG Nasdaq
  • Market Cap
  • CYTK 5.8B
  • JHG 6.9B
  • IPO Year
  • CYTK 2004
  • JHG N/A
  • Fundamental
  • Price
  • CYTK $48.87
  • JHG $42.53
  • Analyst Decision
  • CYTK Buy
  • JHG Hold
  • Analyst Count
  • CYTK 16
  • JHG 11
  • Target Price
  • CYTK $84.07
  • JHG $41.00
  • AVG Volume (30 Days)
  • CYTK 1.2M
  • JHG 1.1M
  • Earning Date
  • CYTK 11-06-2024
  • JHG 01-30-2025
  • Dividend Yield
  • CYTK N/A
  • JHG 3.67%
  • EPS Growth
  • CYTK N/A
  • JHG 24.92
  • EPS
  • CYTK N/A
  • JHG 2.53
  • Revenue
  • CYTK $3,219,000.00
  • JHG $2,333,400,000.00
  • Revenue This Year
  • CYTK N/A
  • JHG $19.66
  • Revenue Next Year
  • CYTK $795.25
  • JHG $7.51
  • P/E Ratio
  • CYTK N/A
  • JHG $16.80
  • Revenue Growth
  • CYTK N/A
  • JHG 13.91
  • 52 Week Low
  • CYTK $43.21
  • JHG $28.19
  • 52 Week High
  • CYTK $110.25
  • JHG $45.74
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 44.62
  • JHG 41.75
  • Support Level
  • CYTK $45.66
  • JHG $43.64
  • Resistance Level
  • CYTK $49.40
  • JHG $44.45
  • Average True Range (ATR)
  • CYTK 1.71
  • JHG 0.85
  • MACD
  • CYTK -0.20
  • JHG -0.41
  • Stochastic Oscillator
  • CYTK 50.79
  • JHG 32.98

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Share on Social Networks: